{"id":515,"date":"2020-09-04T10:57:10","date_gmt":"2020-09-04T10:57:10","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=515"},"modified":"2020-09-04T10:57:10","modified_gmt":"2020-09-04T10:57:10","slug":"02-sep-2020-famotidine-in-combination-with-cetrizine-exhibited-beneficial-reductions-in-inpatient-mortality-and-symptom-progression","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/02-sep-2020-famotidine-in-combination-with-cetrizine-exhibited-beneficial-reductions-in-inpatient-mortality-and-symptom-progression\/","title":{"rendered":"(02 Sep 2020) Famotidine- in combination with cetrizine exhibited beneficial reductions in inpatient mortality and symptom progression"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Dual-Histamine Receptor Blockade with Cetirizine &#8211; Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.pupt.2020.101942<\/p>\n<div _ngcontent-pxe-c4=\"\" class=\"content\">A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a single medical center of 110 high-acuity patients that were treated with cetirizine 10 mg b.i.d. and famotidine 20 mg b.i.d. plus standard-of-care. Of all patients, including those with Do Not Resuscitate directives, receiving the dual-histamine receptor blockade for at least 48 hours, the combination drug treatment resulted in a 16.4% rate of intubation, a 7.3% rate of intubation after a minimum of 48 hours of treatment, a 15.5% rate of inpatient mortality, and 11.0 days duration of hospitalization. The drug combination exhibited beneficial reductions in inpatient mortality and symptom progression when compared to published reports of COVID-19 inpatients. Concomitant medications were assessed and hydroxychloroquine was correlated with worse outcomes. This physician-sponsored cohort study of cetirizine and famotidine provides proof-of-concept of a safe and effective method to reduce the progression in symptom severity, presumably by minimizing the histamine-mediated cytokine storm. Further clinical studies in COVID-19 are warranted of the repurposed off-label combination of two historically-safe histamine receptor blockers.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dual-Histamine Receptor Blockade with Cetirizine &#8211; Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients https:\/\/doi.org\/10.1016\/j.pupt.2020.101942 A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/02-sep-2020-famotidine-in-combination-with-cetrizine-exhibited-beneficial-reductions-in-inpatient-mortality-and-symptom-progression\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(02 Sep 2020) Famotidine- in combination with cetrizine exhibited beneficial reductions in inpatient mortality and symptom progression&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,32],"tags":[33],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/515"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=515"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/515\/revisions"}],"predecessor-version":[{"id":516,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/515\/revisions\/516"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}